URINARY GM2 ACTIVATOR PROTEIN AS A MARKER OF ACUTE RENAL FAILURE OR THE RISK OF DEVELOPING ACUTE RENAL FAILURE
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
May 24, 2012
app pub date -
May 26, 2009
filing date -
May 26, 2009
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
The invention relates to a method of determining the risk of developing acute renal failure (ARF) in an individual, or of determining an ARF, and a method of predicting the progression of an ARF, by detecting and/or quantifying the protein Ganglioside GM2 Activator Protein (GM2AP). The failure can be due to the administration of at least one nephrotoxic agent, wherein the nephrotoxic agent can be an aminoglycoside antibiotic as for example gentamicin.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully